FDA grants Breakthrough Therapy status to NVS's ianalumab for Sjogren's disease with plans for global filings starting in 2026.

Nummular eczema is a debilitating skin condition that is distinct from atopic dermatitis but involves similar disease ...

Pratteln, Switzerland, January 15, 2026 – Santhera Pharmaceuticals (SIX: SANN) announces that the Swiss Agency for Therapeutic Products (Swissmedic), has approved AGAMREE® (vamorolone) for the ...

Subcutaneous anifrolumab (Saphnelo) added to standard therapy significantly improves treatment outcomes in patients with ...

Mild hidradenitis suppurativa is often treated with cycles of steroids and antibiotics that have adverse effects. Can an anti ...

Sensorineural hearing loss (SNHL) is a highly prevalent sensory disorder globally, affecting over 1.5 billion people, with a ...

Asthma and COPD Drugs Market is expected to reach US$ 82.2 Billion by 2036, driven by Advancements in Drug Discovery and ...

Danish dermatology specialist Leo Pharma and its CEO Christophe Bourdon came to San Francisco to attend the J.P. Morgan ...

The global skin-lightening market is worth over $10 billion and growing, but the unregulated products driving it contain ...

In a 10-year propensity-matched cohort study, Irene Tan, MD, of the Einstein Healthcare Network and Jefferson Health in ...

A 45-year-old woman presents with long-standing exertional dyspnea, wheezing, and intermittent dry cough, which has been ongoing for over the past 10 years.

Abivax Provides 2026 Corporate Outlook New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with ...